Mobile Monitor.
Detailed App Info:
Application Description
Are you, or is someone you know, being treated with SPRYCEL® (dasatinib) for Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)? Then you know how important it is to monitor treatment.
INDICATIONS AND USAGE
SPRYCEL® (dasatinib) is a prescription medicine used to treat adults who have:
• newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. The effectiveness of SPRYCEL in these patients is based
on a study that measured two types of response to treatment (cytogenetic and molecular) by 1 year. The study is ongoing to find out how SPRYCEL works over a longer period of time
• Ph+ CML who are no longer benefitting from, or did not tolerate, other treatment including Gleevec®* (imatinib mesylate)
• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who no longer benefit from, or did not tolerate, other treatment
It is not known if SPRYCEL is safe and effective in children younger than 18 years old.
IMPORTANT SAFETY INFORMATION
SPRYCEL may cause serious side effects, including low blood cell counts, bleeding, fluid retention, heart problems, and pulmonary arterial hypertension (PAH). Other common side effects of SPRYCEL include diarrhea, headache, cough, skin rash, fever, nausea, tiredness, vomiting, muscle pain, weakness, and infections. This is not a complete list of all side effects recorded in clinical studies with SPRYCEL. Tell your healthcare provider if you have any side effects while taking SPRYCEL. Please visit http://www.sprycel.com/consumer/sprycel-important-safety-information.aspx for detailed information about potential side effects with SPRYCEL.
Track your treatment step by step, on your iPhone, iPod touch, or iPad. And use it to talk about treatment at your next oncologist visit.
INDICATIONS AND USAGE
SPRYCEL® (dasatinib) is a prescription medicine used to treat adults who have:
• newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. The effectiveness of SPRYCEL in these patients is based
on a study that measured two types of response to treatment (cytogenetic and molecular) by 1 year. The study is ongoing to find out how SPRYCEL works over a longer period of time
• Ph+ CML who are no longer benefitting from, or did not tolerate, other treatment including Gleevec®* (imatinib mesylate)
• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who no longer benefit from, or did not tolerate, other treatment
It is not known if SPRYCEL is safe and effective in children younger than 18 years old.
IMPORTANT SAFETY INFORMATION
SPRYCEL may cause serious side effects, including low blood cell counts, bleeding, fluid retention, heart problems, and pulmonary arterial hypertension (PAH). Other common side effects of SPRYCEL include diarrhea, headache, cough, skin rash, fever, nausea, tiredness, vomiting, muscle pain, weakness, and infections. This is not a complete list of all side effects recorded in clinical studies with SPRYCEL. Tell your healthcare provider if you have any side effects while taking SPRYCEL. Please visit http://www.sprycel.com/consumer/sprycel-important-safety-information.aspx for detailed information about potential side effects with SPRYCEL.
Track your treatment step by step, on your iPhone, iPod touch, or iPad. And use it to talk about treatment at your next oncologist visit.
Requirements
Your mobile device must have at least 2.14 MB of space to download and install Mobile Monitor. app. Mobile Monitor. is available on iTunes for $0.00
If you have any problems with installation or in-app purchase, found bugs, questions, comments about this application, you can visit the official website of Bristol Myers Squibb Bristol-Myers Squibb at http://www.sprycel.com.
Copyright © Bristol-Myers Squibb
